Endocrinology

Why lifestyle advice alone still dominates obesity searches

Despite advances in pharmacotherapy, Google searches for obesity management remain heavily skewed towards lifestyle interventions, indicating a persistent public perception.

Tzield expands its reach: A new option for recently diagnosed pediatric type 1 diabetes

The FDA approved Tzield (teplizumab) for pediatric patients with recently diagnosed Stage 3 type 1 diabetes, marking an expansion of its indication.

Metabolic Syndrome: Is it accelerating your patients' brain aging?

Metabolic syndrome, affecting one in four adults, significantly accelerates brain aging and increases the risk of cognitive decline, impacting neurovascular health.

Weight-Loss Jabs May Create a New Kind of Yo-Yo Dieting

GLP-1 receptor agonists, while effective for weight reduction, present a significant risk of weight regain upon cessation, challenging long-term management strategies.

Online GLP-1 Prescriptions Often Lack Clinical Oversight

Rapid online GLP-1 prescriptions frequently bypass essential clinical assessments, raising concerns about patient safety and appropriate use.

Obesity as Disease: Who Benefits from the Redefinition?

Classifying obesity as a disease shifts focus from lifestyle to medical intervention, benefiting pharmaceutical companies and specific patient subgroups.

Targeted Therapy Reverses Weight Gain From Rare Cause of Obesity

A targeted therapy effectively reversed weight gain in patients with a rare genetic form of obesity, demonstrating significant reductions in body weight.

GLP-1 Agonists, Newer Diabetes Drugs, Linked to Autoimmunity Risk

Newer diabetes treatments, including GLP-1 agonists, carry an elevated risk for autoimmune conditions, requiring careful patient monitoring.

Haaland's 6,000-Calorie Diet: Performance Fuel or Health Risk?

Erling Haaland's reported 6,000-calorie daily diet, while fueling elite athletic performance, presents significant long-term health considerations for the general population.